Farmitalia Carlo Erba S.r.l.

Farmitalia Carlo Erba S.p.a.

Olon S.p.a.

Farmitalia Carlo Erba

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Pharmacia & Upjohn S.p.a.

Antibioticos S.p.a.

Basilea Pharmaceutica Ag

Pharmacia S.p.a.

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori

Marco Alpegiani

Ettore Perrone

Angelo Bedeschi

Maria Ornella Tinti

Sergio Penco

Walter Cabri

Claudio Pisano

Giovanni Franceschi

Pierluigi Bissolino

Franco Zarini

Maurizio Foglio

Paolo Carminati

Giuseppe Cassinelli

Piergiuseppe Orezzi

Paolo Ghetti

Mauro Marzi

Samuele Frigoli

Stephen Hanessian

Loredana Vesci

Franco Zunino

Tania Cristiano

Davide Longoni

Domenico Vergani

Fabrizio Giorgi

Giovanni Pozzi

Daniela Jabes

Costantino D Bruna

Giuseppe Meinardi

Costantino Della Bruna

Patricio Martin Gomez

Riccardo Corigli

Claudio Fuganti

Carlo Battistini

Enrico Pesenti

Giuliano Nannini

Roberta Pizzocaro

Matteo D'Anello

Giuseppe Mazzini

Stefano Serra

Markus Heubes

Giovanni Francheschi

Michael Schleimer

Francesca Abrate

Eugenio Cucchetti

Massimiliano Palladino

Marina Lombroso

Maria Francesca Abrate

Gaetano Balsamo

Constantino Della Bruna

Ettore Negri

Francesco Di Matteo

Vincenzo Rizzo

Giuseppina Visentin

Tamara Danelli

Franco Giudici

Elena Marastoni

Martin Gomez Patricio

Roberto Strigaro

Tamara Ines Danelli

Disclosed is a process for the preparation of Enzalutamide comprising the reaction (Scheme 2), wherein R can be alkyl, aryl, aryl-alkyl or heterocyclyl. 

Process for the preparation of enzalutamide

Disclosed is a process for the synthesis of the active ingredients ospemifene and fispemifene which comprises reacting phenol 4 with an alkylating agent X&#x2014;CHCH&#x2014;Y of formula 7, wherein X is a leaving group and Y is the &#x2014;(OCHCH)OH group wherein n is zero or 1; or X and Y, taken together, represent an oxygen atom; to give ospemifene or fispemifene of formula 8. 

Process for the preparation of ospemifene and fispemifene

Disclosed is a process for the preparation of abiraterone and abiraterone acetate with high yields and purity. A key element of the method is the isolation of a crystalline intermediate that makes the process particularly suitable for implementation on an industrial scale.

Procedure for the preparation of abiraterone acetate and intermediates thereof

Disclosed is a process for the preparation of abiraterone and abiraterone acetate with high yields and purity. A key element of the method is the isolation of a crystalline intermediate that makes the process particularly suitable for implementation on an industrial scale. There is also provided a process for the production of abiraterone acetate by acetylation of abiraterone in the absence of bases or acetylation catalysts.

Disclosed is asenapine phosphate of formula (I) and its enantiomer (I) which can be used to prepare asenapine maleate. Further disclosed is a monoclinic crystalline form of asenapine maleate. 

Crystalline salts of asenapine

The invention relates to a process for the purification of crude abiraterone acetate by treatment with polymer resins in aqueous solvent. The purified product is recovered by simple concentration and filtration.

Process for the purification of abiraterone acetate

Disclosed is a method for the conversion of a compound of formula 3 to a compound 

Process for the preparation of unsaturated trifluoromethanesulfonate steroid derivatives

A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril. 

Crystalline (6R,7R)-7-{2-(5-amino-[1,2,4] thiadiazol-3-yl)-2-[(Z)-trityloxyimino]-acetylamino}-3-[(R)-1'-tert-butoxycarbonyl-2-oxo-[1,3&#x2032;]bipyrrolidinyl-(3E)-ylidenemethyl]-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester; its manufacture and use

Disclosed is a crystalline form of irinotecan hydrochloride (I) and processes for the preparation thereof from crude irinotecan hydrochloride or another polymorphic form of irinotecan. Said crystalline form is particularly suitable for industrial use, because it is easily filtered and possesses characteristics of high stability and purity. 

Crystalline irinotecan hydrochloride and methods for its preparation

A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process.

Stereoselective process and crystalline forms of a camptothecin

Disclosed are salts of the general formula (I) wherein R, Rand B are defined in the description. These salts are useful intermediates for the preparation of cefdinir. Also, disclosed are processes for the preparation thereof from the compounds of the general formula (II) and (III).  Further, disclosed is a method of producing cefdinir from the salts of the general formula (I) including the steps of removing protecting groups.

Intermediate cefdinir salts

Cefdinir crystalline salts of formula (I), in which n ranges from 1 to 3, the preparation and use thereof for the preparation and purification of cefdinir are herein disclosed. The salts of formula (I) can be obtained from cefdinir intermediates or crude cefdinir by treatment with phosphoric acid.

Crystalline cefdinir salts

A compound, which is an amine derivative of formula (I) wherein W is &mdash;CNHOH or &mdash;COOH: R and R are each hydrogen or an organic residue, R is an organic group, Q is a secondary or tertiary acyclic or cyclic amido group, and the pharmaceutically acceptable salts, solvates and hydrates thereof, are inhibitors of matrix metalloproteinases (MMPs) and of the release of tumor necrosis factor-alpha (TNF) from cells. They are therefore useful in the prevention, control and treatment of diseases in which MMPs or TNF are involved, especially tumoral and inflammatory diseases. Processes for their preparation and pharmaceutical compositions containing them are also described.

Matrix metalloproteinase inhibitors

Growing community of inventors

Rodano, Italy

Marco Alpegiani